Understanding how lung cancer treatments work in Latino and Asian patients
Official title: Characterizing treatment responses for common lung cancer (LC) subtypes in Latinos and Asians
Funded at University of California at Davis · NIH-10896249 · Data updated 2026-11-12
This study is looking for genetic clues that can help us understand why some people with lung cancer, especially those with EGFR mutations in Latino and Asian communities, respond differently to certain treatments, so we can create better ways to help everyone fight the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California at Davis NIH-funded |
| Lab location | 1 site (Davis, United States) |
| Project start | August 1, 2023 |
| Project end | July 31, 2028 |
| Funding year | 2024 |
| Award (this year) | $229,826 |
| NIH project number | 5U54CA283766-02 |
| Project ID | NIH-10896249 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with EGFR-mutant non-small cell lung cancer, particularly those of Latino or Asian descent.
✕Less likely to help
Patients with lung cancer who do not have EGFR mutations or those from other ethnic backgrounds may not benefit from this research.
What this research studies
This research focuses on identifying genetic markers that indicate resistance to specific lung cancer treatments in patients with EGFR mutations, particularly among Latino and Asian populations. By analyzing how race, ethnicity, and genetic ancestry influence treatment responses, the study aims to develop better therapeutic strategies that combine existing FDA-approved drugs. Patients will be involved in clinical trials that test these new approaches to improve treatment outcomes for lung cancer. The research will also explore the biological factors that contribute to differences in treatment efficacy among diverse populations.
Why it matters
Potential benefit: If successful, this research could lead to more effective and personalized lung cancer treatments for Latino and Asian patients.
How similar studies have gone: Previous research has shown promising results in targeting genetic markers for treatment resistance in lung cancer, indicating that this approach has potential for success.
Where this research is happening
-
University of California at Davis
Davis, United States Active
Researchers
- Principal investigator: Riess, Jonathan W — University of California at Davis
- Study coordinator: Riess, Jonathan W
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.